Activated T-cell membrane-derived nanocargoes displaying multi-immune checkpoints for enhanced cancer immunotherapy.

ABSTRACT: The advent of immune checkpoint inhibitors (ICIs) has significantly transformed the landscape of cancer treatment in the last decade. However, the efficacy of single-agent ICI remains constrained due to multiple immune checkpoints (ICs)-mediated T cell suppression and inadequate T cell tumor infiltration. Here, we developed a novel approach using activated T-cell membrane-guided nanocarriers to simultaneously block multiple ICs and enhance T-cell infiltration. Initially, primary T cell activation was induced in vitro, and T cells with high expression of ICs were selected to prepare T-cell membrane vesicles. These vesicles were then utilized to coat immunogenic inducer-loaded liposomes (dLNPs) to create nanocarriers termed AM-dLNPs. The AM-dLNPs were demonstrated to effectively inhibit mult

SUBMITTER: Du L 

PROVIDER: S-EPMC12813334 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature